OncoLize is preparing first human trials in pancreatic cancers and other aggressive tumor indications.
We localize the delivery of well-proven drugs inside or next to the tumor. This will increase tumor eradication, reduce side-effects, and keep effective treatment Triple A: Affordable and Accessible for All.
We just closed a first funding round of €1.6 million and will soon start preparing for our Series A of € 8 million for the end of 2024… Join us!
We have shown the concept to work in relevant animal models, we have first patents granted and in advanced national stages and we can scale-up these products at minimal costs. With our extensive experience in setting-up controlled delivery start-up’s we aim to exit at year 6.
That being said, we at OncoLize believe and practice that our products should have impact for global issues. We will make these products available for campaigns in Low- and Middle Income Countries through focused NGO-collaborations.
20th December 2022 OncoLize has joined forces with a small but highly specialized consortium around the department of Engineered Therapeutics led by prof. dr. Jai Prakash from the University of Twente in the Netherlands. The Read more…
14th April 2023. Leiden-based Dutch start-up OncoLize has closed a US$ 1.7 million first round to extend their preclinical success with a localized drug delivery system to treat Pancreatic- and Lung cancer. The round was Read more…
15th December 2022 – The USPTO has granted the patent application valid by RCSI covering the OncoLize technology. This broad base patent describes the composition-of-matter and various formulations and applications essential to the oncology business Read more…